Document Detail

Profibrinolytic, Antithrombotic, and Antiinflammatory Effects of an Insulin-Sensitizing Strategy in Patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.
MedLine Citation:
PMID:  21768545     Owner:  NLM     Status:  Publisher    
Background- Effects were compared in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial of 2 mechanistically different strategies for treatment of hyperglycemia, insulin-sensitizing and insulin-providing strategies, on biomarker profiles reflecting the balance between fibrinolysis and thrombosis and the intensity of inflammation implicated in diabetic vasculopathy. Methods and Results- A total of 2368 patients with type 2 diabetes mellitus and clinically stable, angiographically documented coronary artery disease were randomized to treatment with 1 of the 2 strategies and followed for an average of 5 years. Plasminogen activator inhibitor type 1 antigen and activity, tissue plasminogen activator antigen, fibrinogen, D-dimer, C-reactive protein, insulin, and hemoglobin A(1c) were assayed in blood samples acquired at baseline and at 12 regular intervals throughout the follow-up interval. Higher baseline D-dimer, fibrinogen, and C-reactive protein portended a poor prognosis in patients in both groups. In contrast to the insulin-providing strategy, the insulin-sensitizing strategy led to (1) lower plasma insulin; (2) lower plasminogen activator inhibitor type 1 antigen and activity and lower tissue plasminogen activator antigen (known to track with plasminogen activator inhibitor type 1); and (3) lower C-reactive protein and fibrinogen at all intervals after baseline (P<0.001 for each). Conclusions- The insulin-sensitizing treatment strategy led to changes in biomarker profiles indicative of decreased insulin resistance, an altered balance between thrombosis and fibrinolysis favoring fibrinolysis, and diminished intensity of the systemic inflammatory state, factors that have been associated with cardiovascular risk. Clinical Trial Registration- Unique identifier: NCT00006305.
Burton E Sobel; Regina M Hardison; Saul Genuth; Maria M Brooks; Robert D McBane; David J Schneider; Richard E Pratley; Kurt Huber; Robert Wolk; Ashok Krishnaswami; Robert L Frye;
Related Documents :
1593395 - Health assessments of youngsters with insulin-dependent diabetes.
20955125 - Insulin-dependent diabetes and aeromedical certification - the australian perspective.
21531055 - Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity a...
7050215 - Classification and pathogenesis of the diabetes syndrome: a historical perspective.
19875605 - Autologous umbilical cord blood transfusion in very young children with type 1 diabetes.
20943205 - Andrographolide attenuates tumor necrosis factor-alpha-induced insulin resistance in 3t...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-7-18
Journal Detail:
Title:  Circulation     Volume:  -     ISSN:  1524-4539     ISO Abbreviation:  -     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-7-19     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
University of Vermont, Burlington.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Combined effects of ezetimibe and phytosterols on cholesterol metabolism: a randomized, controlled f...
Next Document:  Polymer-Free Sirolimus- and Probucol-Eluting Versus New Generation Zotarolimus-Eluting Stents in Cor...